Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBAY CymaBay Therapeutics (CBAY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About CymaBay Therapeutics Stock (NASDAQ:CBAY) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.>> Dive into the Workshop Here Get CymaBay Therapeutics alerts:Sign Up Key Stats Today's Range$32.48▼$32.4850-Day Range$32.18▼$32.4852-Week Range$7.26▼$32.50Volume73 shsAverage Volume4.11 million shsMarket Capitalization$3.73 billionP/E RatioN/ADividend YieldN/APrice Target$32.50Consensus RatingHold Company OverviewCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Read More… 625,000% Gain (Ad)The recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.>> Dive into the Workshop Here CymaBay Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks17th Percentile Overall ScoreCBAY MarketRank™: CymaBay Therapeutics scored higher than 17% of companies evaluated by MarketBeat, and ranked 942nd out of 1,020 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingCymaBay Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageCymaBay Therapeutics has received no research coverage in the past 90 days.Read more about CymaBay Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CymaBay Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 12.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CBAY. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.88 Short InterestThere is no current short interest data available for CBAY. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CymaBay Therapeutics' insider trading history. Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CBAY Stock News Headlines3 Biotech Stocks With Revolutionary Pipelines to Buy TodayJuly 29, 2024 | stocknews.comGilead reduces 2024 earnings guidance after completing CymaBay takeoverMarch 22, 2024 | za.investing.comNotice: Major payout due November 19th - are you on the list?On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...October 16, 2024 | Behind the Markets (Ad)Gilead Sciences Completes Acquisition Of CymaBay TherapeuticsMarch 22, 2024 | markets.businessinsider.comGilead Sciences Announces Completion of Acquisition of CymaBayMarch 22, 2024 | businesswire.comCBAY Jul 2024 34.000 callMarch 16, 2024 | finance.yahoo.comCBAY Apr 2024 31.000 putMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 33.000 callMarch 16, 2024 | finance.yahoo.comSee More Headlines CBAY Stock Analysis - Frequently Asked Questions How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.42 million. What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CymaBay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings2/28/2024Today10/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees101Year FoundedN/APrice Target and Rating Average Stock Price Target$32.50 High Stock Price Target$32.50 Low Stock Price Target$32.50 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,370,000.00 Net MarginsN/A Pretax Margin-339.11% Return on Equity-50.72% Return on Assets-31.04% Debt Debt-to-Equity RatioN/A Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$31.07 million Price / Sales119.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book12.59Miscellaneous Outstanding Shares114,724,000Free Float106,693,000Market Cap$3.73 billion OptionableOptionable Beta0.32 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:CBAY) was last updated on 10/16/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CymaBay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.